CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
晚期黑色素瘤的细胞治疗
英文原题：Cellular Therapy for Advanced Melanoma.
查看英文原题
Cellular Therapy for Advanced Melanoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
过去40年间，细胞疗法逐渐成为治疗晚期黑色素瘤的方法。首种TIL（肿瘤浸润淋巴细胞）疗法lifileucel于2024年获美国食品药品监督管理局批准，用于既往接受过抗PD-1治疗及BRAF抑制剂治疗（BRAF V600突变型疾病）的转移性黑色素瘤患者。TIL疗法进一步临床开发有望带来更安全、更有效的策略。黑色素瘤细胞疗法也已超越TIL疗法，靶向黑色素瘤抗原的TCR转导T细胞产品和T细胞衔接型双特异性药物均已显示抗肿瘤活性。
展开英文摘要原文
Cellular therapy has been an evolving therapeutic approach in advanced melanoma over the past 40 y. The first tumor infiltrating lymphocyte (TIL) therapy, lifileucil, was Food and Drug Administration-approved in 2024 for patients with metastatic melanoma who have previously been treated with an anti-PD-1 therapy and BRAF inhibitor (BRAF V600 mutant disease).
Further clinical development of TIL therapy will hopefully lead to safer and more effective strategies. Cellular therapy in melanoma has also expanded beyond TIL therapy with anti-tumor activity demonstrated for TCR-transduced T-cell products and T-cell engager bi-specific agents that target melanoma antigens.
论文信息
- 作者
- Zaemes J、Gibney GT
- 第一作者单位
- Department of Medicine, Division of Medical Oncology, Harvard Medical School, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215, USA.Israel
- 通讯作者单位
- Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC, USA. Electronic address: geoffrey.t.gibney@gunet.georgetown.edu.United States
- 文献类型
- 综述
- 期刊
- The Surgical clinics of North America2025 Jun
- 原文标识
- PubMed 40412894 · DOI 10.1016/j.suc.2025.03.004